Sustained Improvement of Muscle Function One Year after Full-Length Dystrophin Gene Transfer into mdx Mice by a Gutted Helper-Dependent Adenoviral Vector

Human Gene Therapy

Volumn 15, Issue 2, 2004, Pages 145-156

  Dudley, Roy W R ^a   Lu, Yifan ^b   Gilbert, Rénald ^c   Matecki, Stefan ^a   Nalbantoglu, Josephine ^b   Petrof, Basil J ^a   Karpati, George ^b  

^a MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c NATIONAL RESEARCH COUNCIL CANADA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; DYSTROPHIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL INFILTRATION; CONTROLLED STUDY; GENE TRANSFER; HELPER CELL; HISTOPATHOLOGY; HUMORAL IMMUNITY; MOUSE; MUSCLE CONTRACTILITY; MUSCLE CONTRACTION; MUSCLE FUNCTION; MUSCLE HYPERTROPHY; MUSCLE INJURY; MUSCLE ISOMETRIC CONTRACTION; NEWBORN; NONHUMAN; PHAGOCYTE; PROGRESSIVE MUSCULAR DYSTROPHY; PROTEIN EXPRESSION; SARCOLEMMA;

ADENOVIRIDAE; ANIMALS; ANIMALS, NEWBORN; CYTOSKELETAL PROTEINS; DNA; DYSTROGLYCANS; DYSTROPHIN; GENE EXPRESSION REGULATION; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HELPER VIRUSES; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED MDX; MUSCLE CONTRACTION; MUSCULAR DYSTROPHY, DUCHENNE; TIME FACTORS; TRANSDUCTION, GENETIC;

ADENOVIRIDAE; ANIMALIA; MURINAE;

EID: 1142273131     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/104303404772679959     Document Type: Article

References (50)

1. ACSADI, G., LOCHMULLER, H., JANI, A., HUARD, J., MASSIE, B., PRESCOTT, S., SIMONEAU, M., PETROF, B.J., and KARPATI, G. (1996). Dystrophin expression in muscles of mdx mice after adenovirus-mediated in vivo gene transfer. Hum. Gene Ther. 7, 129-140.
2. AHMAD, A., BRINSON, M., HODGES, B.L., CHAMBERLAIN, J.S., and AMALFITANO, A. (2000). Mdx mice inducibly expressing dystrophin provide insights into the potential of gene therapy for Duchenne muscular dystrophy. Hum. Mol. Genet. 9, 2507-2515.
3. BLAKE, D.J., WEIR, A., NEWEY, S.E., and DAVIES, K.E. (2002). Function and genetics of dystrophin and dystrophin-related proteins in muscle. Physiol. Rev. 82, 291-329.
4. CHEN, H.H., MACK, L.M., CHOI, S.Y., ONTELL, M., KOCHANEK, S., and CLEMENS, P.R. (1999). DNA from both high-capacity and first-generation adenoviral vectors remains intact in skeletal muscle. Hum. Gene Ther. 10, 365-373.
5. DECONINCK, N., RAGOT, T., MARECHAL, G., PERRICAUDET, M., and GILLIS, J.M. (1996). Functional protection of dystrophic mouse (mdx) muscles after adenovirus-mediated transfer of a dystrophin minigene. Proc. Natl. Acad. Sci. U.S.A. 93, 3570-3574.
6. DELLORUSSO, C., SCOTT, J.M., HARTIGAN-O'CONNOR, D., SALVATORI, G., BARJOT, C., ROBINSON, A.S., CRAWFORD, R.W., BROOKS, S.V., and CHAMBERLAIN, J.S. (2002). Functional correction of adult mdx mouse muscle using gutted adenoviral vectors expressing full-length dystrophin. Proc. Natl. Acad. Sci. U.S.A. 99, 12979-12984.
7. EBIHARA, S., GUIBINGA, G.H., GILBERT, R., NALBANTOGLU, J., MASSIE, B., KARPATI, G., and PETROF, B.J. (2000). Differential effects of dystrophin and utrophin gene transfer in immunocompetent muscular dystrophy (mdx) mice. Physiol. Genomics 3, 133-144.
8. ERVASTI, J.M., and CAMPBELL, K.P. (1993). Dystrophin-associated glycoproteins: Their possible roles in the pathogenesis of Duchenne muscular dystrophy. Mol. Cell Biol. Hum. Dis. Ser. 3, 139-166.
9. ERVASTI, J.M., OHLENDIECK, K., KAHL, S.D., GAVER, M.G., and CAMPBELL, K.P. (1990). Deficiency of a glycoprotein component of the dystrophin complex in dystrophic muscle. Nature 345, 315-319.
10. FABB, S.A., WELLS, D.J., SERPENTE, P., and DICKSON, G. (2002). Adeno-associated virus vector gene transfer and sarcolemmal expression of a 144 kDa micro-dystrophin effectively restores the dystrophin-associated protein complex and inhibits myofibre degeneration in nude/mdx mice. Hum. Mol. Genet. 11, 733-741.
11. FISHER, K.J., CHOI, H., BURDA, J., CHEN, S.J., and WILSON, J.M. (1996). Recombinant adenovirus deleted of all viral genes for gene therapy of cystic fibrosis. Virology 217, 11-22.
12. GILBERT, R., NALBANTOGLU, J., TINSLEY, J.M., MASSIE, B., DAVIES, K.E., and KARPATI, G. (1998). Efficient utrophin expression following adenovirus gene transfer in dystrophic muscle. Biochem. Biophys. Res. Commun. 242, 244-247.
13. GILBERT, R., NALBANTOGLU, J., PETROF, B.J., EBIHARA, S., GUIBINGA, G.H., TINSLEY, J.M., KAMEN, A., MASSIE, B., DAVIES, K.E., and KARPATI, G. (1999). Adenovirus-mediated utrophin gene transfer mitigates the dystrophic phenotype of mdx mouse muscles. Hum. Gene Ther. 10, 1299-1310.
14. GILBERT, R., NALBANTOGLU, J., HOWELL, J.M., DAVIES, L., FLETCHER, S., AMALFITANO, A., PETROF, B.J., KAMEN, A., MASSIE, B., and KARPATI, G. (2001). Dystrophin expression in muscle following gene transfer with a fully deleted ("gutted") adenovirus is markedly improved by trans-acting adenoviral gene products. Hum. Gene Ther. 12, 1741-1755.
15. GILBERT, R., LIU, A., PETROF, B., NALBANTOGLU, J., and KARPATI, G. (2002). Improved performance of a fully gutted adenovirus vector containing two full-length dystrophin cDNAs regulated by a strong promoter. Mol. Ther. 6, 501-509.
16. GILBERT, R., DUDLEY, R.W., LIU, A.B., PETROF, B.J., NALBANTOGLU, J., and KARPATI, G. (2003). Prolonged dystrophin expression and functional correction of mdx mouse muscle following gene transfer with a helper-dependent (gutted) adenovirus-encoding murine dystrophin. Hum. Mol. Genet. 12, 1287-1299.
17. GILCHRIST, S.C., ONTELL, M.P., KOCHANEK, S., and CLEMENS, P.R. (2002). Immune response to full-length dystrophin delivered to Dmd muscle by a high-capacity adenoviral vector. Mol. Ther. 6, 359-368.
18. GILLIS, J.M. (1999). Understanding dystrophinopathies: An inventory of the structural and functional consequences of the absence of dystrophin in muscles of the mdx mouse. J. Muscle Res. Cell Motil. 20, 605-625,
19. HOFFMAN, E.P. (2001). Dystrophinopathies. In Disorders of Voluntary Muscle. G. Karpati, D. Hilton-Jones, and R.C. Griggs, eds. (Cambridge University Press, Cambridge, UK) pp. 385-432.
20. HOFFMAN, E.P., BROWN, R.H., Jr., and KUNKEL, L.M. (1987). Dystrophin: The protein product of the Duchenne muscular dystrophy locus. Cell 51, 919-928.
21. HOFFMAN, E.P., MORGAN, J.E., WATKINS, S.C., and PARTRIDGE, T.A. (1990). Somatic reversion/suppression of the mouse mdx phenotype in vivo. J. Neurol. Sci. 99, 9-25.
22. KARPATI, G., CARPENTER, S., and PRESCOTT, S. (1988). Small-caliber skeletal muscle fibers do not suffer necrosis in mdx mouse dystrophy. Muscle Nerve 11, 795-803.
23. KOBINGER, G.P., LOUBOUTIN, J.P., BARTON, E.R., SWEENEY, H.L., and WILSON, J.M. (2003). Correction of the dystrophic phenotype by in vivo targeting of muscle progenitor cells. Hum. Gene Ther. 14, 1441-1449.
24. KOCHANEK, S., CLEMENS, P.R., MITANI, K., CHEN, H.H., CHAN, S., and CASKEY, C.T. (1996). A new adenoviral vector: Replacement of all viral coding sequences with 28 kb of DNA independently expressing both full-length dystrophin and beta-galactosidase. Proc. Natl. Acad. Sci. U.S.A. 93, 5731-5736.
25. KUMAR-SINGH, R., and CHAMBERLAIN, J.S. (1996). Encapsidated adenovirus minichromosomes allow delivery and expression of a 14 kb dystrophin cDNA to muscle cells. Hum. Mol. Genet. 5, 913-921.
26. LAW, D.J., and TIDBALL, J.G. (1993). Dystrophin deficiency is associated with myotendinous junction defects in prenecrotic and fully regenerated skeletal muscle. Am. J. Pathol. 142, 1513-1523.
27. MAIONE, D., WIZNEROWICZ, M., DELMASTRO, P., CORTESE, R., CILIBERTO, G., LA MONICA, N., and SAVINO, R. (2000). Prolonged expression and effective readministration of erythropoietin delivered with a fully deleted adenoviral vector. Hum. Gene Ther. 11, 859-868.
28. MITTEREDER, N., MARCH, K.L., and TRAPNELL, B.C. (1996). Evaluation of the concentration and bioactivity of adenovirus vectors for gene therapy. J. Virol. 70, 7498-7509.
29. MOENS, P., BAATSEN, P.H., and MARECHAL, G. (1993). Increased susceptibility of EDL muscles from mdx mice to damage induced by contractions with stretch. J. Muscle Res. Cell. Motil. 14, 446-451.
30. MORSY, M.A., GU, M., MOTZEL, S., ZHAO, J., LIN, J., SU, Q., ALLEN, H., FRANLIN, L., PARKS, R.J., GRAHAM, F.L., KOCHANEK, S., BETT, A.J., and CASKEY, C.T. (1998). An adenoviral vector deleted for all viral coding sequences results in enhanced safety and extended expression of a leptin transgene. Proc. Natl. Acad. Sci. U.S.A. 95, 7866-7871.
31. NYBERG-HOFFMAN, C., SHABRAM, P., LI, W., GIROUX, D., and AGUILAR-CORDOVA, E. (1997). Sensitivity and reproducibility in adenoviral infectious titer determination. Nat. Med. 3, 808-811.
32. OHLENDIECK, K., and CAMPBELL, K.P. (1991). Dystrophin-associated proteins are greatly reduced in skeletal muscle from mdx mice. J. Cell Biol. 115, 1685-1694.
33. OHLENDIECK, K., MATSUMURA, K., IONASESCU, V.V., TOWBIN, J.A., BOSCH, E.P., WEINSTEIN, S.L., SERNETT, S.W., and CAMPBELL, K.P. (1993). Duchenne muscular dystrophy: Deficiency of dystrophin-associated proteins in the sarcolemma. Neurology 43, 795-800.
34. PARKS, R.J., CHEN, L., ANTON, M., SANKAR, U., RUDNICKI, M.A., and GRAHAM, F.L. (1996). A helper-dependent adenovirus vector system: removal of helper virus by Cre-mediated excision of the viral packaging signal. Proc. Natl. Acad. Sci. U.S.A. 93, 13565-13570.
35. PETROF, B.J., SHRAGER, J.B., STEDMAN, H.H., KELLY, A.M., and SWEENEY, H.L. (1993). Dystrophin protects the sarcolemma from stresses developed during muscle contraction. Proc. Natl. Acad. Sci. U.S.A. 90, 3710-3714.
36. PHELPS, S.F., HAUSER, M.A., COLE, N.M., RAFAEL, J.A., HINKLE, R.T., FAULKNER, J.A., and CHAMBERLAIN, J.S. (1995). Expression of full-length and truncated dystrophin minigenes in transgenic mdx mice. Hum. Mol. Genet. 4, 1251-1258.
37. SAMITT, C.E., and BONILLA, E. (1990). Immunocytochemical study of dystrophin at the myotendinous junction. Muscle Nerve 13, 493-500.
38. SCHIEDNER, G., MORRAL, N., PARKS, R.J., WU, Y., KOOPMANS, S.C., LANGSTON, C., GRAHAM, F.L., BEAUDET, A.L., and KOCHANEK, S. (1998). Genomic DNA transfer with a high-capacity adenovirus vector results in improved in vivo gene expression and decreased toxicity. Nat. Genet. 18, 180-183.
39. SICINSKI, P., GENG, Y., RYDER-COOK, A.S., BARNARD, E.A., DARLISON, M.G., and BARNARD, P.J. (1989). The molecular basis of muscular dystrophy in the mdx mouse: a point mutation. Science 244, 1578-1580.
40. SNYDER, R.O. (1999). Adeno-associated virus-mediated gene delivery. J. Gene Med. 1, 166-175.
41. SPENCER, M.J., MONTECINO-RODRIGUEZ, E., DORSHKIND, K., and TIDBALL, J.G. (2001). Helper (CD4(+)) and cytotoxic (CD8(+)) T cells promote the pathology of dystrophin-deficient muscle. Clin. Immunol. 98, 235-243.
42. STRAUB, V., RAFAEL, J.A., CHAMBERLAIN, J.S., and CAMPBELL, K.P. (1997). Animal models for muscular dystrophy show different patterns of sarcolemmal disruption. J. Cell. Biol. 139, 375-385.
43. VINCENT, N., RAGOT, T., GILGENKRANTZ, H., COUTON, D., CHAFEY, P., GREGOIRE, A., BRIAND, P., KAPLAN, J.C., KAHN, A., and PERRICAUDET, M. (1993). Long-term correction of mouse dystrophic degeneration by adenovirus-mediated transfer of a minidystrophin gene. Nat. Genet. 5, 130-134.
44. WANG, B., LI, J., and XIAO, X. (2000). Adeno-associated virus vector carrying human minidystrophin genes effectively ameliorates muscular dystrophy in mdx mouse model. Proc. Natl. Acad. Sci. U.S.A. 97, 13714-13719.
45. WATCHKO, J., O'DAY, T., WANG, B., ZHOU, L., TANG, Y., LI, J., and XIAO, X. (2002). Adeno-associated virus vector-mediated minidystrophin gene therapy improves dystrophic muscle contractile function in mdx mice. Hum. Gene Ther. 13, 1451-1460.
46. WELLER, B., KARPATI, G., and CARPENTER, S. (1990). Dystrophin-deficient mdx muscle fibers are preferentially vulnerable to necrosis induced by experimental lengthening contractions. J. Neurol. Sci. 100, 9-13.
47. YANG, L., LOCHMULLER, H., LUO, J., MASSIE, B., NALBANTOGLU, J., KARPATI, G., and PETROF, B.J. (1998). Adenovirus-mediated dystrophin minigene transfer improves muscle strength in adult dystrophic (MDX) mice. Gene Ther. 5, 369-379.
48. YANG, Y., NUNES, F.A., BERENCSI, K., GONCZOL, E., ENGELHARDT, J.F., and WILSON, J.M. (1994a). Inactivation of E2a in recombinant adenoviruses improves the prospect for gene therapy in cystic fibrosis. Nat. Genet. 7, 362-369.
49. YANG, Y., NUNES, F.A., BERENCSI, K., FURTH, E.E., GONCZOL, E., and WILSON, J.M. (1994b). Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. Proc. Natl. Acad. Sci. U.S.A. 91, 4407-4411.
50. ZOU, L., ZHOU, H., PASTORE, L., and YANG, K. (2000). Prolonged transgene expression mediated by a helper-dependent adenoviral vector (HDAd) in the central nervous system. Mol. Ther. 2, 105-113.